These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [Puberty and growth development in patients with a 21-hydroxylase defect]. Börger D, Willig RP. Monatsschr Kinderheilkd; 1985 Nov; 133(11):828-33. PubMed ID: 2934617 [Abstract] [Full Text] [Related]
5. [Growth and adult height in patients with congenital adrenal hyperplasia]. Kolousková S, Zemková D, Snajderová M, Lebl J. Cas Lek Cesk; 1995 Nov 01; 134(21):689-91. PubMed ID: 8556761 [Abstract] [Full Text] [Related]
12. Growth pattern and final height in 21-hydroxylase deficiency. Bajpai A, Pandey RM, Kabra M, Menon PS. Indian Pediatr; 2007 Oct 01; 44(10):771-3. PubMed ID: 17998577 [Abstract] [Full Text] [Related]
13. Growth hormone (GH) treatment to final height in children with idiopathic short stature: evidence for a dose effect. Wit JM, Rekers-Mombarg LT, Cutler GB, Crowe B, Beck TJ, Roberts K, Gill A, Chaussain JL, Frisch H, Yturriaga R, Attanasio AF. J Pediatr; 2005 Jan 01; 146(1):45-53. PubMed ID: 15644821 [Abstract] [Full Text] [Related]
14. Growth patterns and outcomes in congenital adrenal hyperplasia; effect of chronic treatment regimens. Rasat R, Espiner EA, Abbott GD. N Z Med J; 1995 Aug 11; 108(1005):311-4. PubMed ID: 7644165 [Abstract] [Full Text] [Related]
20. HYDROCORTISONE THERAPY AND GROWTH TRAJECTORY IN CHILDREN WITH CLASSICAL CONGENITAL ADRENAL HYPERPLASIA. Bizzarri C, Improda N, Maggioli C, Capalbo D, Roma S, Porzio O, Salerno M, Cappa M. Endocr Pract; 2017 May 11; 23(5):546-556. PubMed ID: 28225306 [Abstract] [Full Text] [Related] Page: [Next] [New Search]